Dr. Ho is combining the development of electronic health record-based phenotype algorithms to identify and subtype chronic kidney diseases with MyCode genetic and whole exome data to identify underlying molecular pathways through genome-wide association analysis with collaborators in KHRI, Biomedical & Translational Informatics, Genomic Medicine Institute. His current focus has been on Type 2 diabetic kidney disease and chronic kidney disease. He is a member of the international CKDGen Consortium with its mission to identify novel genetic loci associated with kidney function and kidney disease through GWAS meta-analysis, the Chronic Kidney Disease Prognosis Consortium (CKD-PC), a participant in the eMERGE Network, and PI for the Fabry Registry at Geisinger. He and his collaborators are recipients of a major grant from the Geisinger Health Plan to develop and study the effectiveness of integrated EHR-based bioinformatics and clinical intervention pathways targeting patients developing acute kidney injury and its clinical sequelae at Geisinger Medical Center.
- Soman S, Yee J, Ho K. (2015, Oct). Quality improvement initiatives in kidney disease. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL, eds. Brenner and Rector's The Kidney. 10th ed. Philadelphia, PA: Elsevier
- Ho K, McKnight AJ. (2014). The changing landscape of diabetic kidney disease: new reflections on phenotype, classification and disease progression, to influence future investigative studies and therapeutic trials. Adv. Chronic Kidney Dis , 21(3): 256-259.
EducationBS, Harvard College, 1978-1982
MD, Columbia School of Medicine, 1983-1987
Internal Medicine Residency, New York Presbyterian Hospital, 1987-1990
Nephrology Research Fellowship, Harvard Medical School, 1990-1993
Nephrology Clinical Fellowship, Harvard Medical School, 1993-1994